Gut Microbe Lactobacillus plantarum Shows Modest Weight Loss Benefits in Major Meta-Analysis

A common bacterium found in fermented foods and dietary supplements may offer people with obesity a small but genuine helping hand, according to one of the most rigorous analyses of the evidence published to date. A team of researchers from Khyber Medical College and collaborating institutions in Pakistan has conducted a systematic review and meta-analysis of randomized controlled trials examining Lactobacillus plantarum, a probiotic species increasingly marketed for weight management. Their findings, published in the International Journal of Obesity, suggest that supplementation with this microbe produces measurable reductions in body weight, body mass index, and waist circumference in adults with a body mass index of 25 kilograms per square meter or higher. The effect sizes are modest, but the analysis, which applied the GRADE framework to rate confidence in each result, concluded that the evidence supporting weight reduction was of high certainty, a designation few probiotic outcomes ever achieve.

The scale of the question matters. Obesity now affects more than one billion people worldwide and is rooted in a web of chronic low-grade inflammation, metabolic dysfunction, and disruption of the gut microbiota, the trillions of microbes that inhabit the human intestine. Current pharmacological options such as GLP-1 receptor agonists have transformed the treatment landscape, yet they remain expensive, demand long-term adherence, and can carry side effects that lead many patients to discontinue treatment. Against that backdrop, researchers have intensively explored whether live bacteria could tilt the metabolic balance in a favorable direction. Lactobacillus plantarum has attracted particular attention because animal and mechanistic studies indicate it can alter intestinal microbial communities, improve serum metabolic profiles, modulate immune signaling, and even influence liver enzymes associated with fatty liver disease. Human trials, however, have produced a confusing mixture of positive, neutral, and negative results, leaving clinicians without a clear verdict.

To resolve that uncertainty, the research team followed PRISMA reporting guidelines and prospectively registered their protocol on PROSPERO under the identifier CRD420251102722. They systematically searched PubMed, the Cochrane Library, and Google Scholar through May 2025, ultimately identifying eighteen randomized controlled trials encompassing 1,310 participants. To be eligible, studies had to enroll non-diabetic adults with a body mass index of at least 25 kilograms per square meter and compare Lactobacillus plantarum supplementation against a control group. The primary outcomes were body weight and BMI; secondary outcomes included lipid profiles, glycemic indices, inflammatory biomarkers, liver enzymes, and body composition measures such as fat mass and waist circumference. Each trial was appraised for risk of bias using the revised Cochrane RoB 2.0 tool, and the certainty of evidence for every outcome was graded with GRADE, which penalizes findings for inconsistency, imprecision, indirectness, and publication bias.

The headline result was a statistically significant reduction in body weight. Across the pooled trials, supplementation with Lactobacillus plantarum produced a mean difference of minus 1.23 kilograms compared with controls, with a 95 percent confidence interval stretching from minus 1.97 to minus 0.49 kilograms and a p value of 0.001. Heterogeneity was moderate, with an I-squared statistic of 49 percent, meaning roughly half of the variation between studies could be explained by chance rather than real differences in effects. BMI fell by a mean of 0.28 units per square meter, and waist circumference shrank by an average of 1.36 centimeters, a finding with a p value of 0.003 that is notable because abdominal fat is the depot most strongly linked to cardiometabolic risk. The analysis also documented improvements in liver enzymes, suggesting a possible hepatoprotective signal that aligns with mechanistic work showing the bacterium can dampen oxidative stress in liver tissue.

Perhaps the most consequential judgment the authors made was about how much to trust these numbers. They assigned high certainty to the body weight finding, the strongest rating available, and moderate certainty to the reductions in BMI, waist circumference, fat mass, and liver enzymes. In contrast, the evidence for improvements in lipids, glycemic measures, and inflammatory biomarkers was rated only low certainty. This layered assessment is important because inflammatory and lipid outcomes have often driven enthusiastic claims about probiotics. Here, the GRADE analysis effectively tempers that enthusiasm: while the anthropometric effects rest on solid footing, the immunometabolic benefits remain provisional and require better-designed trials before they can be considered established.

The subgroup analysis offered a tantalizing hint about formulation. Reductions in weight and BMI appeared more pronounced in trials that used multi-strain formulations containing Lactobacillus plantarum alongside other species than in trials testing single-strain supplements. However, the formal tests for subgroup interaction were non-significant, and the authors were careful to note that this means the evidence is insufficient to confirm a true difference in effect by formulation type. The observation is biologically plausible, since microbial communities often function through redundancy and cross-feeding networks in which complementary strains reinforce one another’s metabolic activities. Still, the statistical caution here is a model of restrained interpretation in a field frequently criticized for overstating strain-specific claims.

How could a stomach-dwelling bacterium nudge body weight downward at all? Several mechanisms have support from the broader literature cited in the analysis. Probiotics can modulate the composition and function of the gut microbiota, which in turn affects energy harvest from the diet, production of short-chain fatty acids, and the integrity of the intestinal barrier. A weakened barrier allows bacterial products such as lipopolysaccharide to enter circulation, fueling the systemic low-grade inflammation, sometimes called metaflammation, that underpins insulin resistance and adipose tissue dysfunction. Lactobacillus plantarum strains have also been shown to influence appetite-regulating hormones and adipocytokines, reduce anti-adipogenic signaling pathways, and alter bile acid metabolism, all of which could plausibly contribute to modest weight reduction. Trials included in the review tested a wide range of delivery formats, from fermented milk and yogurt to capsules and powders, and several specific strains such as OLL2712, Dad-13, K50, LMT1-48, and SKO-001 appeared in individual studies.

The authors of the new analysis interpret the effect size candidly. A reduction of roughly 1.2 kilograms will not rival the double-digit weight losses achievable with newer medications, but the literature on intentional weight loss shows that even modest reductions of 2 to 5 percent of body weight can improve cardiovascular risk factors, and probiotic supplementation carries a favorable safety profile in the trials reviewed. In that sense, the findings position Lactobacillus plantarum not as a replacement for established therapies but as a potential adjunct, one that might be layered onto lifestyle interventions at low cost and low risk. The improvements in liver enzymes add further interest given the rising prevalence of non-alcoholic fatty liver disease, which shares the same metabolic soil as obesity and currently has limited approved pharmacological treatments.

Limitations remain. The eighteen trials varied in strain, dose, duration, and delivery vehicle, and the moderate to high heterogeneity in the BMI analysis signals genuine diversity in how participants and interventions behaved across studies. Most trials were relatively short, and no pooled estimate speaks to whether weight loss persists after supplementation stops. The exclusion of participants with diabetes narrows the applicability of the findings to that large patient group. The authors call for standardized, long-term randomized trials that specify strains, doses, and populations in ways that allow direct comparison. Until those trials arrive, the meta-analysis provides the clearest synthesis yet of what this popular probiotic actually does: it delivers a small, statistically reliable, and high-certainty reduction in body weight in adults with overweight or obesity, with moderate-certainty support for slimmer waistlines, less fat mass, and healthier liver enzyme levels, while claims about lipids, blood sugar, and inflammation await stronger evidence.

Subject of Research: The effects of Lactobacillus plantarum probiotic supplementation on anthropometric and inflammatory parameters in adults with obesity, evaluated through a GRADE-assessed systematic review and meta-analysis of randomized controlled trials.

Article Title: Influence of Lactobacillus plantarum on anthropometric and inflammatory parameters in obesity: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials

Article References: Khattak, M. H., Abbas, S. A., Zaryab, U., Bibi, H., Siddiqui, S. A., Khan, B. W., Zeeshan, N., Khan, M. F., Amjad, M. M., Khan, N. A., Mehmood, Y., & Khan, H. W. (2026). Influence of Lactobacillus plantarum on anthropometric and inflammatory parameters in obesity: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02221-0

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02221-0

Keywords: Lactobacillus plantarum, probiotics, obesity, meta-analysis, body weight, body mass index, waist circumference, gut microbiota, inflammation, liver enzymes, randomized controlled trials, GRADE